Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | RHEB | Q15382 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23938203 | 0.84 | CYP17A1 (0.33) | CYP1A2CYP17A1TLR8TSHR | |
| SCHEMBL24729953 | 0.79 | — | — | |
| SCHEMBL1290821 | 0.76 | NR4A3 (0.42) | TLR8TSHR | |
| SCHEMBL21863437 | 0.75 | DRD2 (0.41) | CYP1A2CYP17A1TLR8MEN1KMT2A | |
| SCHEMBL1290672 | 0.74 | KDM4E (0.41) | CYP1A2MEN1KMT2ACYP2C19TSHR | |
| SCHEMBL25045802 | 0.72 | DRD2 (0.40) | CYP1A2CYP17A1TLR8 | |
| SCHEMBL24103795 | 0.72 | TSHR (0.36) | CYP1A2CYP17A1TLR8MEN1KMT2A | |
| SCHEMBL21893906 | 0.69 | PDE4B (0.33) | CYP1A2CYP17A1TLR8MEN1KMT2A | |
| SCHEMBL12145712 | 0.67 | DRD4 (0.41) | CYP1A2CYP17A1ELANETSHR | |
| SCHEMBL9288787 | 0.66 | POLB (0.43) | CYP1A2MEN1KMT2ACYP2C19ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO EARLY DISCOVERY, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | CYP1A2 2136/4885CYP17A1 3468/4885TLR8 3437/4885 |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | USP28, USP25, USP24 | CYP1A2 2136/4885CYP17A1 3468/4885TLR8 3437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.